Moderna Q2 preview: Where next for MRNA stock?

When will Moderna release Q2 earnings?

Moderna is scheduled to release second quarter earnings before US markets open on Wednesday August 3. The company will hold a conference call on the same day at 0800 ET.

Moderna Q2 earnings consensus

Wall Street forecasts revenue will drop 7.6% in the second quarter to $4.0 billion and diluted EPS is expected to plunge 30% to $4.54.

Moderna Q2 earnings preview

Moderna is expected to report the first drop in sales since it started making serious sums selling its Covid-19 vaccine when it reports second quarter results this week.

Hype around Covid-19 vaccine makers has waned this year as the pandemic has eased, and the attention will remain on how demand is shaping up and whether governments are still committed to jabbing against sub-variants. Investors will be hopeful it can reiterate its guidance to strike signed purchase agreements worth $21 billion in 2022.

Moderna has said it expects to secure slightly more orders in the second half compared to the first. The company has only announced one major new deal since its last set of results, having agreed to sell 66 million doses of its vaccine to the US government as it continues with its booster programme. That is worth some $1.74 billion, and the government has an option to purchase another 234 million doses which, based on the price of the initial round of jabs, could be worth another $6.2 billion. That will provide some confidence that governments remain committed to jabbing their populations.

While the focus remains on its Covid-19 drug, it is hoping to release up to three respiratory drugs in the next two to three years if everything goes to plan. A new vaccine targeting the BA.4/5 sub-variant is on its way, although this could cause softness in the meantime if buyers decide to wait for the new jab.

Markets remain uncertain what this year will hold for Moderna. Wall Street’s revenue forecasts remain wide for 2022, ranging from a low of $20.3 billion to a high of $25.9 billion (with a mean of $22.0 billion). Diluted EPS is forecast to dip 2.9% in 2022 following the landmark profit made last year, which was the first it has recorded since inception.

Where next for MRNA stock?

Moderna shares were thrusted into overbought territory after hitting its highest level in over two months at $176 last month, suggesting this could be a tough ceiling to crack for the stock. The fact trading volumes over the last 10 sessions are almost half the 100-day average supports the view that it could struggle to break above this level without a new catalyst. If it can, then the March-high of $188 comes into view, followed by the 200-day moving average at $193. Notably, the 20 brokers that cover the stock see slightly more upside potential with an average target price of $221, where it last sat in early 2022.

On the downside, the 50-day and 100-day moving averages that have converged around the $150 mark can be treated as an initial floor for the stock going forward, although we could see it falter back toward $120 if it comes under renewed pressure. The 18-month low of $116 should be regarded as the ultimate floor.

How to trade Moderna stock

You can trade Moderna shares with Forex.com in just four steps:

Open a Forex.com account, or log-in if you’re already a customer.
Search for ‘Moderna’ in our award-winning platform
Choose your position and size, and your stop and limit levels
Place the trade

Or you can try out your trading strategy risk-free by signing up for our Demo Account.

StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please ensure you fully understand the risks involved by reading our full risk warning.

FOREX.com is a trading name of StoneX Europe Limited, and FOREX.com/ie is a domain operated by StoneX Europe Ltd, a member of StoneX Group Inc. StoneX Europe Ltd, is a Cyprus Investment Firm (CIF) company registered to the Department of Registrar of Companies and Official Receiver with a Registration Number HE409708, and authorized and regulated by the Cyprus Securities & Exchange Commission (CySEC) under license number 400/21. StoneX Europe is a Member of the Investor Compensation Fund (ICF) and has its registered address at Nikokreontos 2, 5th Floor, 1066 Nicosia, Cyprus.

StoneX Europe Limited is registered with the German Federal Financial Supervisory Authority (BaFin). BaFin registration ID: 10160255

FOREX.com is a trademark of StoneX Europe Ltd, a member of StoneX Group Inc.

The statistical data and the awards received refer to the Global FOREX.com brand.

This website uses cookies to provide you with the very best experience and to know you better. By visiting our website with your browser set to allow cookies, you consent to our use of cookies as described in our Privacy Policy.

Through passporting, StoneX Europe is allowed to provide its services and products on a cross-border basis to the following European Economic Area ("EEA") states: Austria, Bulgaria, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden.

Additionally, StoneX Europe Ltd is allowed to provide Investment and Ancillary Services to the following non-EU jurisdiction: Switzerland.

StoneX Europe Ltd products, services and information are not intended for residents other than the ones stated above.

Tied Agent Information: KQ Markets Europe Ltd with Company No. HE427857.
Address: Athalassas 62, Mezzanine, Strovolos, Nicosia Cyprus.
Services Provided: Reception and Transmission of Orders.
Commencement Date: 06/12/2022
Website: KQ Markets - CFD Trading | KQ Markets

We may pay inducements, such as commissions or fees, to affiliates or third-party introducers for referring clients to us. This is in line with regulatory guidelines and fully disclosed where applicable.

StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation. StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.